GLP1R and Alzheimer disease: Numerous studies have consistently shown that GLP-1R agonists like liraglutide, exenatide, and lixisenatide possess the capacity to mitigate neuroinflammation in models of Alzheimer’s disease (AD), leading to an improvement in cognitive function.